Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)

201674 citationsJournal Articlehybrid Open Access

Authors

Toshitaka Nakamura

Masao Fukunaga · Kawasaki Medical School

Tsuyoshi Nakano · Kumamoto Central Hospital

Hiroyuki Kishimoto · Kajima Corporation (Japan)

M. Ito · Nagasaki University

Hiroshi Hagino · Tottori University

Teruki Sone · Kawasaki Medical School

Abstract

Once-yearly administration of ZOL 5 mg to Japanese patients with primary osteoporosis reduced the risk of new morphometric vertebral fractures and was found to be safe.

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone and Joint Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Osteoporosis International

Volume 28, Issue 1, pp. 389-398

DOI: 10.1007/s00198-016-3736-y

Field-Weighted Citation Impact: 5.25